ARS Pharmaceuticals (NASDAQ:SPRY) and Critical Outcome Technologies (OTCMKTS:COTQF) Critical Comparison

Critical Outcome Technologies (OTCMKTS:COTQF) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Critical Outcome Technologies and ARS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Critical Outcome Technologies	N/A	N/A	N/A
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%

Analyst Ratings

This is a summary of current recommendations for Critical Outcome Technologies and ARS Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Critical Outcome Technologies	0	0	0	0	0.00
ARS Pharmaceuticals	1	1	3	0	2.40

ARS Pharmaceuticals has a consensus target price of $28.25, indicating a potential upside of 227.35%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Critical Outcome Technologies.

Institutional & Insider Ownership

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Critical Outcome Technologies and ARS Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A
ARS Pharmaceuticals	$84.28 million	10.17	-$171.30 million	($1.75)	-4.93

Critical Outcome Technologies has higher earnings, but lower revenue than ARS Pharmaceuticals.

Summary

ARS Pharmaceuticals beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.